Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CHEMM.CO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CHEMM.CO and 80,000+ other tickers.
See exactly how CHEMM.CO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CHEMM.CO and 80,000+ other tickers.
Headquartered in Allerød, Denmark, and established in 1997, ChemoMetec A/S focuses on the design, production, and worldwide distribution of analytical instruments for cell enumeration and analysis. Their sophisticated solutions are utilized across diverse fields, including cell-based therapeutics, oncology and stem cell research, pharmaceutical development and manufacturing, along with quality assurance for animal semen and beer. The company's product offerings feature a range of NucleoCounter devices, such as the NC-3000 advanced image cytometer, the NC-250 automated cell analyzer, and the…
No recent news available.